Camidge, D. R., Barlesi, F., Goldman, J., Morgensztern, D., Heist, R., Vokes, E., … Kelly, K. (2019). MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. In Journal of Thoracic Oncology (Vol. 14, pp. S305–S306). Elsevier BV. https://doi.org/10.1016/j.jtho.2019.08.612

Camidge, D. R., F. Barlesi, J. Goldman, D. Morgensztern, R. Heist, E. Vokes, A. Spira, et al. “MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer.” In Journal of Thoracic Oncology, 14:S305–6. Elsevier BV, 2019. https://doi.org/10.1016/j.jtho.2019.08.612.

Camidge DR, Barlesi F, Goldman J, Morgensztern D, Heist R, Vokes E, et al. MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. In: Journal of Thoracic Oncology. Elsevier BV; 2019. p. S305–6.

Camidge, D. R., et al. “MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology, vol. 14, no. 10, Elsevier BV, 2019, pp. S305–06. Crossref, doi:10.1016/j.jtho.2019.08.612.

Camidge DR, Barlesi F, Goldman J, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su W, Hong D, Strickler J, Motwani M, Sun Z, Parikh A, Komarnitsky P, Wu J, Kelly K. MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. Elsevier BV; 2019. p. S305–S306.